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Introduction: ATP-binding cassette subfamily B member 1 (ABCB1) and subfamily C member 10 (ABCC10) proteins
are efflux transporters that couple the energy derived from ATP hydrolysis to the translocation of toxic substances
and chemotherapeutic drugs out of cells. Cabazitaxel is a novel taxane that differs from paclitaxel by its lower
affinity for ATP-binding cassette (ABC) transporters.
Methods: We determined the effects of cabazitaxel, a novel tubulin-binding taxane, and paclitaxel on paclitaxel-
resistant, ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells and paclitaxel-resistant, ABCC10-overexpressing
HEK293/ABCC10 cells by calculating the degree of drug resistance and measuring ATPase activity of the
ABCB1 transporter.
Results: Decreased resistance to cabazitaxel compared with paclitaxel was observed in KB-C2, LLC-MDR1-WT, and
HEK293/ABCC10 cells. Moreover, cabazitaxel had low efficacy, whereas paclitaxel had high efficacy in stimulating
the ATPase activity of ABCB1, indicating a direct interaction of both drugs with the transporter.
Conclusion: ABCB1 and ABCC10 are not primary resistance factors for cabazitaxel compared with paclitaxel,
suggesting that cabazitaxel may have a low affinity for these efflux transporters.
Keywords: ATP-binding cassette (ABC) transporters, ATP-binding cassette subfamily B member 1 (ABCB1),
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Paclitaxel is a clinically used chemotherapeutic drug, but
its use can elicit resistance to various anticancer drugs
in certain types of cancers [1]. The efficacy of paclitaxel
can be attenuated by the overexpression of multidrug ef-
flux transporters, altered metabolism, decreased sensitiv-
ity to apoptosis, alterations in microtubule dynamics,
diminished interactions of paclitaxel with its cellular
target, and genetic polymorphisms [1,2]. These afore-
mentioned mechanisms of resistance typically produce
chemotherapeutic failure. ATP-binding cassette subfam-
ily B member 1 [ABCB1, also called multidrug resistance
1 (MDR1) or P-glycoprotein (P-gp)] and ATP-binding* Correspondence: ashbyc@stjohns.edu; chenz@stjohns.edu
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unless otherwise stated.cassette subfamily C member 10 [ABCC10, also called
multidrug resistance protein 7 (MRP7)] have been well
characterized in terms of their capacities to confer resist-
ance to paclitaxel [1,3-5]. The human ABCB1 transporter,
a product encoded by the ABCB1 gene, which is localized
to chromosome 7p21, is the first identified mammalian
ATP-binding cassette (ABC) transporter [6,7]. The ABCB1
transporter has a molecular weight of 170 kDa and com-
prises two transmembrane-binding domains (TMD1 and
TMD2) and two nucleotide-binding domains (NBD1 and
NBD2) [4,8]. The human ABCC10 transporter is encoded
by the ABCC10 gene, which is localized to chromosome
6p21.1 [9,10]. The ABCC10 transporter is a 171-kDa
protein, containing three membrane-spanning domains
(MSD1, MSD2, and MSD3) and two NBDs. It belongs
to the class of long ABCCs that includes ABCC1,
ABCC2, ABCC3, and ABCC6 [11].tral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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for use by the United States Food and Drug Administra-
tion and is derived from 10-deacetyl-baccatin III, which
is extracted from European yew needles [12]. Mechanistic-
ally, cabazitaxel exerts its cytotoxic effects by 1) binding to
tubulin and promoting its assembly into microtubules
while simultaneously inhibiting microtubule disassembly
and 2) stabilizing microtubules, resulting in the inhibition
of mitotic and interphase cellular functions [13]. It has
been postulated that cancer cells expressing ABCB1 be-
come resistant to taxanes [14]. Apart from ABCB1, the
ABCC10 transcript has also been detected in several
adenocarcinomas, including breast, ovarian, and lung tu-
mors. This is of potential interest because the latter tu-
mors are treated with taxanes. The ABCC10 transcript
and ABCC10 protein were reported to be induced by vin-
cristine exposure in two salivary gland adenocarcinoma
cell lines that are cross-resistant to docetaxel, and the
ABCC10 transcript was reported to be increased in MCF7
cells by exposure to doxorubicin. Moreover, ABCC10 is
induced by paclitaxel in a non-small cell lung cancer cell
line [3,15]. Our previous studies reported that ABCB1 and
ABCC10 confer resistance to two classes of drugs that
target microtubules: Vinca alkaloids and taxanes [1,16,17].
It was therefore of interest to determine if ABCB1 and
ABCC10 might also confer resistance to new anti-
microtubule drugs. Thus, we hypothesized that ABCB1
and ABCC10 may confer differential resistance to pacli-
taxel and cabazitaxel. In this study, we determined the
sensitivity of ABCB1- and ABCC10-overexpressing cells
to paclitaxel and cabazitaxel in vitro.
Methods
Materials
Cabazitaxel was purchased from MedChemexpress
(Manmouth Junction, NJ, USA). Paclitaxel was pur-
chased from Tocris Bioscience (Ellisville, MO, USA).
Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum (FBS), phosphate-buffered saline (PBS),
10,000 IU/mL penicillin and 10,000 μg/mL strepto-
mycin, and 0.25% trypsin were purchased from HyClone
(Waltham, MA, USA). 3-(4,5-Dimethylthiazol-yl)-2,5-di-
phenyltetrazolium bromide (MTT), dimethyl sulfoxide
(DMSO), ammonium molybdate, 2-(N-morpholino) etha-
nesulfonic acid (MES) hydrate, antimony potassium tar-
trate, sodium azide, and N-methyl-D-glucamine were
obtained from Sigma Chemical Co. (St. Louis, MO, USA).
Potassium phosphate, ethylene glycol tetraacetic acid
(EGTA), and adenosine triphosphate (ATP) were products
of AMRESCO (Solon, OH, USA). Sulfuric acid solution
(37 N) was purchased from Fisher Scientific (Pittsburgh,
PA, USA). KCl was purchased from Avantor Performance
Materials (Center Valley, PA, USA). Ouabain was pur-
chased from Enzo Life Sciences, Inc. (Farmingdale, NY,USA). Dithiothreitol was purchased from Promega Cor-
poration (Madison, WI, USA). MgCl2 was purchased
from EMD Millipore (Billerica, MA, USA). Ascorbic
acid was purchased from VWR International (West
Chester, PA, USA). Sodium orthovanadate was purchased
from Alfa Aesar (Ward Hill, MA, USA). The OPSYS mi-
croplate reader was purchased from Dynex Technologies
(Chantilly, VA, USA).Cell lines
The ABCB1-overexpressing KB-C2 cell line was estab-
lished by a step-wise exposure of KB-3-1 cells, a parental
human epidermoid carcinoma cell line, to increasing
concentrations (up to 2 μg/mL) of colchicine [18]. The
LLC-PK1 porcine renal epithelial cells were transfected
with wild-type human ABCB1 cDNA plasmid as previ-
ously described, and the stable transfectant cell line was
named LLC-MDR1-WT [19]. HEK293/pcDNA3.1 and
HEK293/ABCC10 cells were generated by transfecting
HEK293 cells with an empty vector and an ABCC10 ex-
pression vector, respectively [20]. We thank Dr. Shinichi
Akiyama (Kagoshima University, Japan) for the KB-3-1
and KB-C2 cell lines, Dr. Michael M. Gottesman (NCI,
NIH, USA) for the LLC-PK1 and LLC-MDR1-WT cell
lines, and Dr. Gary D. Kruh (University of Illinois at
Chicago, IL, USA) for the ABCC10 plasmid.Drug sensitivity
To determine the drug sensitivities of the previously de-
scribed ABCB1-overexpressing KB-C2 cells, LLC-MDR1-
WT cells, and ABCC10-overexpressing HEK293/ABCC10
cells, with KB-3-1, LLC-PK1, and HEK293/pcDNA3.1
cells as the respective controls [1,16], a modified MTT
assay was performed [1,21]. Approximately 4,000 KB-3-1
cells, 7,000 KB-C2 cells, and 5,000 LLC-PK1, LLC-
MDR1-WT, HEK293/pcDNA3.1, and HEK293/ABCC10
cells were seeded in 180 μL of medium in each well of
96-well plates. After incubating for 24 h at 37°C, 20 μL
of paclitaxel or cabazitaxel (0.01 to 10 μmol/L) was
added. Subsequently, cells treated with paclitaxel or caba-
zitaxel in DMEM supplemented with 10% FBS were incu-
bated at 37°C for 72 h. After 72 h, 20 μL MTT (4 mg/mL)
was added to each well. The cells were incubated at 37°C
for another 4 h. The MTT with medium was removed,
and 100 μL of DMSO was added to each well. The absorb-
ance was measured at 570 nm by an Opsys microplate
reader (Dynex Technologies, VA, USA). The degree of
resistance was calculated by dividing the 50% inhibition
concentration (IC50) as calculated using the Bliss method
for drug-resistant cells (KB-C2, LLC-MDR1-WT, and
HEK293/ABCC10) by that of the parental drug-sensitive
cells (KB-3-1, LLC-PK1, and HEK293/pcDNA3.1), re-
spectively. Each MTT assay was run in triplicate.
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The ABCB1 transporter uses energy derived from the hy-
drolysis of ATP to efflux their substrates across the mem-
brane against a concentration gradient; thus, the ATP
consumption reflects the ATPase activity of the trans-
porter. The vanadate (Vi)-sensitive ATPase activity of
ABCB1 in the membrane vesicles of High Five insect cells
[(His)-6-tagged ABCB1 expressed in Trichoplusia ni cells
using the recombinant baculovirus system and purified by
metal affinity chromatography] was measured as previ-
ously described [22,23]. The membrane vesicles (10–
20 μg protein/reaction) were incubated in ATPase assay
buffer (50 mmol/L MES-Tris, pH 6.8, 50 mmol/L KCl,
5 mmol/L sodium azide, 1 mmol/L EGTA, 1 mmol/L oua-
bain, 2 mmol/L dithiothreitol, and 10 mmol/L MgCl2) at
37°C for 5 min with or without 0.3 mmol/L vanadate. The
membrane vesicles in ATPase assay buffer were incubated
with different concentrations (0–10 μmol/L) of paclitaxel
or cabazitaxel at 37°C for 3 min, and then 5 mmol/L ATP
was added at 37°C. After 20 min of incubation, the reac-
tion was terminated by adding 0.1 mL of 5% SDS solution.
The amount of Pi released was quantified at 800 nm using
a Bio-Rad SmartSpec Plus Spectrophotometer (Hercules,
CA, USA) as previously described [23,24].
Statistical analyses
All experiments were repeated at least three times. The
differences between runs were assessed using the two-
tailed Student’s t-test, and statistical significance was
determined at P < 0.05. Microsoft Office Excel 2010, li-
censed from Microsoft (Redmond, WA, USA), was used
for data processing and analysis.
Results
Cytotoxicity of paclitaxel and cabazitaxel in ABCB1- and
ABCC10-overexpressing cells
As shown in Table 1, significantly elevated resistance to
paclitaxel was observed for the ABCB1-overexpressing,
drug-selective KB-C2 cells and ABCB1-transfected LLC-
MDR1-WT cells, which exhibited 21.2- and 25.6-fold re-
sistance as compared with those of the parental KB-3-1Table 1 Drug sensitivities of ABCB1- and ABCC10-overexpress
Cell line IC50 of paclitaxel (nmol/L) FR
KB-3-1 11.7 ± 2.7 21.2
KB-C2 249.4 ± 60.9
LLC-PK1 30.5 ± 2.2 25.6
LLC-MDR1-WT 781.9 ± 70.2
HEK293/pcDNA3.1 12.8 ± 1.4 9.3
HEK293/ABCC10 119.2 ± 15.7
IC50, 50% inhibition concentration; FR, fold resistance. All IC50 values are expressed
values of paclitaxel or cabazitaxel for resistant cells (KB-C2, LLC-MDR1-WT, or HEK29
or HEK293/pcDNA3.1 cells, respectively). The values in the table are representativeand LLC-PK1 cells, respectively; weakly elevated resistance
to cabazitaxel was observed for KB-C2 and LLC-MDR1-
WT cells, which exhibited 2.2- and 9.1-fold resistance as
compared with those of KB-3-1 and LLC-PK1 cells,
respectively. In addition, the resistance of ABCC10-
overexpressing cells to paclitaxel and cabazitaxel was
analyzed. The ABCC10-transfected HEK293/ABCC10
cells exhibited a 9.3-fold resistance to paclitaxel and 1.0-
fold resistance to cabazitaxel as compared with those of
HEK293/pcDNA3.1 cells. Representative concentration-
response curves for paclitaxel and cabazitaxel are shown
in Figure 1.
Effects of paclitaxel and cabazitaxel on ABCB1 ATP
hydrolysis
Paclitaxel and cabazitaxel stimulated the ATPase activity
of ABCB1 (Figure 2), suggesting that paclitaxel and caba-
zitaxel interact at the drug substrate-binding site and
increase the ATPase activity of ABCB1. However, less
stimulation of the ATPase activity of ABCB1 was observed
with cabazitaxel as compared with paclitaxel, suggesting
that cabazitaxel has a lower affinity for ABCB1, consistent
with the cytotoxicity results.
Discussion
In the present study, ABCB1-overexpressing, drug-selective
KB-C2 cells and ABCB1-transfected LLC-MDR1-WT
cells showed low resistance to cabazitaxel. ABCC10-
overexpressing HEK293/ABCC10 cells exhibited no re-
sistance to cabazitaxel as compared with their resistance
to paclitaxel. Furthermore, cabazitaxel stimulated the
ATPase activity of ABCB1 to a lesser magnitude than
paclitaxel.
The present analysis of ABCB1 and ABCC10 efflux
transporters provides important and new information on
the resistance profile related to these pumps. A notable
feature of ABCB1 and ABCC10 that emerged from this
line of investigation is that these pumps are able to confer
little or no resistance to cabazitaxel. Of the microtubule-
stabilizing drugs recently used in clinical development,
cabazitaxel is the most advanced one [12]. As such,ing cells
P value IC50 of cabazitaxel (nmol/L) FR P value
0.031 13.9 ± 5.5 2.2 0.114
31.2 ± 7.1
0.004 27.9 ± 0.7 9.1 0.001
255.1 ± 12.2
0.010 12.5 ± 2.1 1.0 0.799
13.1 ± 1.8
as the mean ± standard deviation (SD). FR was calculated by dividing the IC50
3/ABCC10 cells) by those for the parental sensitive cells (KB-3-1, LLC-PK1,
of at least 3 independent experiments.
Figure 1 Cytotoxicity of paclitaxel and cabazitaxel in ABCB1- and ABCC10-overexpressing cells. ABCB1, ATP-binding cassette subfamily B
member 1; ABCC10, ATP-binding cassette subfamily C member 10. The cytotoxicity of paclitaxel and cabazitaxel was determined by the MTT assay in
ABCB1-overexpressing KB-C2 and LLC-MDR1-WT cells, ABCC10-overexpressing HEK293/ABCC10 cells, and their parental KB-3-1, LLC-PK1, and HEK293/
pcDNA3.1 cells. Error bars indicate the standard deviation (SD). Significantly elevated resistance of KB-C2 (A) and LLC-MDR1-WT cells (C) to paclitaxel,
none or low-level resistance of KB-C2 (B) and LLC-MDR1-WT cells (D) to cabazitaxel, significantly elevated resistance of HEK293/ABCC10 cells to
paclitaxel (E), and no resistance of HEK293/ABCC10 cells to cabazitaxel (F) are observed as compared with those of their parental cells.
Figure 2 Stimulation of ABCB1 ATPase activity by paclitaxel and cabazitaxel. Vanadate-sensitive ABCB1 ATPase activity was stimulated in
the presence of the indicated concentrations of paclitaxel and cabazitaxel. Error bars indicate the SD.
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ously tested drug efflux pump [25]. Our results suggest
that the differential resistance properties of ABCB1- and
ABCC10-overexpressing cells to paclitaxel and cabazitaxel
may be attributed to structural differences of these drugs,
although this remains to be determined.
Duran et al. [26] reported several potential biomarkers
for predicting cabazitaxel resistance in cell lines that did
not express the ABCB1 protein; these biomarkers in-
cluded reduced breast cancer type 1 susceptibility protein
(BRCA1) expression and increased class III β-tubulin
isotype expression. Moreover, alterations in microtubule
dynamics and induction of the epithelial-mesenchymal
transition have been linked to the resistance mechanism
of cabazitaxel [26]. Thus, it is possible that the drug-
resistant cell lines used in our study may express the
aforementioned markers and confer resistance to caba-
zitaxel. Therefore, future experiments will be directed
toward determining the mechanisms that mediate caba-
zitaxel resistance by various methods, such as measur-
ing the cellular retention of cabazitaxel in cell lines that
are positive and negative for ABC transporters.
Conclusions
In conclusion, cabazitaxel, unlike paclitaxel, sensitizes
ABCB1- and ABCC10-overexpressing cells. It is possible
that cabazitaxel is a low-affinity substrate of ABCB1 and
ABCC10 and that these transporters may not play a role
in the development of drug resistance in the clinic.
However, further preclinical studies are warranted to es-
tablish this fact.
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